Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

The contribution of targeted therapy to the neoadjuvant chemoradiation of rectal cancer.

Torino F, Sarmiento R, Gasparini G.

Crit Rev Oncol Hematol. 2013 Sep;87(3):283-305. doi: 10.1016/j.critrevonc.2013.02.002. Review.

PMID:
23478150
2.

A phase II trial of neoadjuvant IMRT-based chemoradiotherapy followed by one cycle of capecitabine for stage II/III rectal adenocarcinoma.

Zhu J, Gu W, Lian P, Sheng W, Cai G, Shi D, Cai S, Zhang Z.

Radiat Oncol. 2013 May 29;8:130. doi: 10.1186/1748-717X-8-130.

3.

The role of targeted agents in preoperative chemoradiation for rectal cancer.

Wadlow RC, Ryan DP.

Cancer. 2010 Aug 1;116(15):3537-48. doi: 10.1002/cncr.25155. Review.

4.

Randomized phase II--study evaluating EGFR targeting therapy with cetuximab in combination with radiotherapy and chemotherapy for patients with locally advanced pancreatic cancer--PARC: study protocol [ISRCTN56652283].

Krempien R, Muenter MW, Huber PE, Nill S, Friess H, Timke C, Didinger B, Buechler P, Heeger S, Herfarth KK, Abdollahi A, Buchler MW, Debus J.

BMC Cancer. 2005 Oct 11;5:131.

5.

Neoadjuvant chemotherapy prior to preoperative chemoradiation or radiation in rectal cancer: should we be more cautious?

Glynne-Jones R, Grainger J, Harrison M, Ostler P, Makris A.

Br J Cancer. 2006 Feb 13;94(3):363-71. Review.

6.

Beyond 5-fluorouracil: the emerging role of newer chemotherapeutics and targeted agents with radiation therapy.

Czito BG, Willett CG.

Semin Radiat Oncol. 2011 Jul;21(3):203-11. doi: 10.1016/j.semradonc.2011.02.006. Review.

PMID:
21645865
7.

A safety and survival analysis of neoadjuvant bevacizumab with standard chemoradiation in a phase I/II study compared with standard chemoradiation in locally advanced rectal cancer.

Willett CG, Duda DG, Ancukiewicz M, Shah M, Czito BG, Bentley R, Poleski M, Fujita H, Lauwers GY, Carroll M, Tyler D, Mantyh C, Shellito P, Chung DC, Clark JW, Jain RK.

Oncologist. 2010;15(8):845-51. doi: 10.1634/theoncologist.2010-0030.

8.

Role of combined-modality therapy in the management of locally advanced rectal cancer.

Hosein PJ, Rocha-Lima CM.

Clin Colorectal Cancer. 2008 Nov;7(6):369-75. doi: 10.3816/CCC.2008.n.049. Review.

PMID:
19036689
9.
10.

Neoadjuvant therapy of rectal cancer new treatment perspectives.

De Paoli A, Innocente R, Buonadonna A, Boz G, Sigon R, Canzonieri V, Frustaci S.

Tumori. 2004 Jul-Aug;90(4):373-8. Review.

PMID:
15510978
11.

Multidisciplinary management of locally advanced rectal cancer: neoadjuvant approaches.

Murugappan S, Harris WP, Willett CG, Lin E.

J Natl Compr Canc Netw. 2013 May 1;11(5):548-57. Review.

PMID:
23667205
12.

Multidisciplinary Management of Locally Advanced Rectal Cancer--An Evolving Landscape?

Lee M, Gibbs P, Wong R.

Clin Colorectal Cancer. 2015 Dec;14(4):251-61. doi: 10.1016/j.clcc.2015.06.002. Review.

PMID:
26210575
13.

Current issues in the targeted therapy of advanced colorectal cancer.

Knijn N, Tol J, Punt CJ.

Discov Med. 2010 Apr;9(47):328-36. Review.

14.

Recurrence rates and prognostic factors in ypN0 rectal cancer after neoadjuvant chemoradiation and total mesorectal excision.

Govindarajan A, Reidy D, Weiser MR, Paty PB, Temple LK, Guillem JG, Saltz LB, Wong WD, Nash GM.

Ann Surg Oncol. 2011 Dec;18(13):3666-72. doi: 10.1245/s10434-011-1788-y.

PMID:
21590450
15.

Expression of epidermal growth factor receptor as a predictive factor for rectal cancer.

Motlagh A, Azadeh P, Fazlalizadeh A, Shahrad B, Shafaghi B, Fudazi M, Yosefi A, Davaei M.

Arch Iran Med. 2007 Jul;10(3):301-8.

16.

[Prognostic significance of changes of tumor epidermal growth factor receptor expression after neoadjuvant chemoradiation in patients with rectal adenocarcinoma].

Dvorak J, Sitorova V, Ryska A, Sirak I, Richter I, Hatlova J, Ferko A, Melichar B, Petera J.

Strahlenther Onkol. 2012 Sep;188(9):833-8.

PMID:
22847519
17.

Biomarkers for cetuximab-based neoadjuvant radiochemotherapy in locally advanced rectal cancer.

Grimminger PP, Danenberg P, Dellas K, Arnold D, Rödel C, Machiels JP, Haustermans K, Debucquoy A, Velenik V, Sempoux C, Bracko M, Hölscher AH, Semrau R, Yang D, Danenberg K, Lenz HJ, Vallböhmer D.

Clin Cancer Res. 2011 May 15;17(10):3469-77. doi: 10.1158/1078-0432.CCR-10-2273.

18.

Multidisciplinary treatment of locally advanced rectal cancer: a literature review. Part 1.

Berardi R, Maccaroni E, Onofri A, Giampieri R, Bittoni A, Pistelli M, Scartozzi M, Pierantoni C, Bianconi M, Cascinu S.

Expert Opin Pharmacother. 2009 Oct;10(14):2245-58. doi: 10.1517/14656560903143776. Review.

PMID:
19640208
19.

A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer.

Gasparini G, Torino F, Ueno T, Cascinu S, Troiani T, Ballestrero A, Berardi R, Shishido J, Yoshizawa A, Mori Y, Nagayama S, Morosini P, Toi M.

Angiogenesis. 2012 Mar;15(1):141-50. doi: 10.1007/s10456-011-9250-0.

PMID:
22212406
20.

Should preoperative or postoperative therapy be administered in the management of rectal cancer?

Kachnic LA.

Semin Oncol. 2006 Dec;33(6 Suppl 11):S64-9. Review.

PMID:
17178291
Items per page

Supplemental Content

Support Center